Yongqi Dong

Dr. Yongqi Dong

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2022 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
PDF file
YDYongqi Dong
Yongqi Dong
SHSong He
Song He
XLXue Li
Xue Li
ZZZhihang Zhou
Zhihang Zhou
Whether the use of acid suppressants can reduce non-vitamin K oral anticoagulants (NOACs)-related gastrointestinal bleeding (GIB) remains unclear. To systemically evaluate the effect of acid suppressants on the risk of GIB in patients treated with NOACs. All related studies were searched in four databases (Cochrane, Embase, PubMed, and Web of Science) from their establishment to August 10, 2021. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used to identify studies and Stata 16.0 software was used for meta-analysis, including sensitivity and subgroup analysis. Six retrospective cohort studies were included in this study. The use of acid suppressants significantly reduced the GIB risk in patients taking NOACs, with an overall relative risk (RR) of 0.70 (95% confidence interval [CI]: 0.61-0.82; P < 0.001; I2 = 56.3%). This trend of reduced risk for GIB in NOACs was more significant in upper GIB (UGIB; RR: 0.45; 95%CI: 0.22-0.90; P = 0.025; I2 = 71.1%). The reduction was stronger for dabigatran than for rivaroxaban and apixaban. The least reduction in the risk of GIB with acid suppressant co-therapy was rivaroxaban (dabigatran: RR: 0.53; 95% CI: 0.45-0.62; P = <0.001; I2 = 39.8%; apixaban: RR: 0.67; 95% CI: 0.54-0.84; P = <0.001; I2 = 0; rivaroxaban: RR: 0.73; 95% CI: 0.66-0.81; P = <0.001; I2 = 37.6%). The included studies revealed the protective effect of acid suppressants against NOACs-related GIB, especially in the upper gastrointestinal tract. The protective effect was even stronger in patients using dabigatran than in those using Xa inhibitors (rivaroxaban and apixaban).

1 November 2024 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
SXShiyong Xiao
Shiyong Xiao
YDYongqi Dong
Yongqi Dong
YXYuan Xia
Yuan Xia
HXHongyan Xu
Hongyan Xu
FWFalin Weng
Falin Weng
CAChengming Ai
Chengming Ai
Background: In recent years, there has been a growing focus on chronic non-communicable diseases (NCD) and their impact on personal and social health. Effective management of NCD is essential for their prevention and treatment. This study aims to utilize bibliometric methods to analyze and summarize the current development and emerging trends in NCD management. Methods: A literature search and screening were conducted on the Web of Science Core Collection database from January 1, 2004, to December 31, 2023. VOSviewer and Citespace software was performed to examine publication volume, authors, institutions, countries, journals, citation frequencies, keywords, clustering, and burst terms, and to create a visual map. Results: A total of 996 valid publications from 464 journals were included in the study. The number of publications exhibited a gradual growth trend over the years. The United States was the most productive and influential country, contributing the highest proportion of both publications and total citations. BMC Health Services Research, Toronto University, and Marshall, Bruce C. were identified as the most productive journal, institution, and author, respectively. Further analysis of keyword co-occurrence and burst detection revealed that the most prevalent keywords were “improving primary care” and “integrated care”. Conclusion: This bibliometric analysis provides a comprehensive overview of the current status and trends in NCD management over the past two decades, providing valuable insights for future research directions. It indicates a potential shift towards enhancing primary healthy care, integrated care, and digital health.

20 April 2026 in Liver International
Verified
Journal Article
Closed access
YDYongqi Dong
Yongqi Dong
DZDan Zhou
Dan Zhou
LZLeyu Zhou
Leyu Zhou
LYLi Yang
Li Yang
YSYi Shen
Yi Shen

18 July 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
Xin GongXin Gong
Xin Gong
YXYinxia Xu
Yinxia Xu
YHYong Hao
Yong Hao
MYMeitao Yi
Meitao Yi
CYChao Yuan
Chao Yuan
YDYongqi Dong
Yongqi Dong
Background: Laryngeal cancer (LC) is the most prevalent form of head and neck cancer, significantly impacting patients' health. Occupational exposure to sulfuric acid (OESA) and asbestos (OEA) is a recognized risk factor for LC, but the associated mortality burden remains unclear. This study aimed to evaluate the global trends of LC attributable to OESA and OEA, and to project future trends.Methods: Based on the Global Burden of Disease Study 2021, we analyzed the number of deaths, age-standardized death rates (ASDR), and estimated annual percentage changes by age, sex, and socio-demographic index (SDI) of LC attributed to OESA and OEA. Decomposition analysis was used to identify the drivers of disease burden changes. Frontier analysis was used to estimate achievable outcomes based on development levels. Additionally, Bayesian age-period-cohort model was used to predict future trends up to 2040.Results: In 2021, global LC deaths attributable to OESA and OEA were 3,612.35 (95% uncertainty intervals (UI): 1,504.31–6,492.29) and 3,392.00 (95% UI: 1,892.13–5,134.88), respectively, representing increases of 37.5% and 21.4%, respectively, from 1990. The ASDRs for OESA and OEA in 2021 were both 0.04 per 100,000 (95% UI: 0.02–0.07 and 0.02–0.06, respectively), both lower than in 1990. LC deaths attributable to OESA and OEA mainly occur in elderly patients, and men consistently showed higher LC deaths and ASDR than females. The ASDR for OESA was negatively correlated with the SDI, while OEA was positively correlated. Decomposition analysis highlighted differences in disease burden drivers across SDI regions. Frontier analysis showed that countries like Cuba and Pakistan were farthest from the OESA-related mortality burden frontier, while Monaco and Lesotho were farthest from OEA-related mortality burden. From 2022 to 2040, LC deaths attributable to OESA and OEA are projected to increase to 4,810.90 (95% UI: 1,628.04–8,010.74) and 3,648.48 (95% UI: 1,016.75–6,322.42), respectively.Conclusions: Although the ASDR decreased from 1990 to 2021, OESA and OEA remain contributors to LC mortality worldwide, with the number of deaths expected to increase over the next two decades. Disease burden varies significantly across SDI regions, suggesting that preventive measures should be tailored to specific SDI levels.

14 June 2023 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
HCHaiyan Cao
Haiyan Cao
HXHongyan Xu
Hongyan Xu
MZMin Zhu
Min Zhu
XCXinglin Chu
Xinglin Chu
ZZZhihuan Zhang
Zhihuan Zhang
YDYongqi Dong
Yongqi Dong
Rivaroxaban is a direct oral anticoagulant with the highest risk of anticoagulant-induced major gastrointestinal bleeding (MGIB). Currently, there is a lack of tools to identify patients at high risk of rivaroxaban-induced MGIB. To establish a nomogram model to predict the risk of MGIB in patients receiving rivaroxaban. Demographic information, comorbidities, concomitant medications, and laboratory test results were collected from 356 patients (178 diagnosed with MGIB) who were taking rivaroxaban between January 2013 and June 2021. Univariate and multivariate logistic regression analyses were used to identify the independent predictors of MGIB, and a nomogram was constructed based on these predictors. A receiver operating characteristic curve, Brier score, calibration plot, decision curve, and internal validation was used to evaluate the calibration, discrimination, and clinical usefulness of the nomogram. Age, haemoglobin level, platelet count, creatinine level, prior peptic ulcer disease, prior bleeding, prior stroke, proton pump inhibitor use, and antiplatelet agent use were independent predictors of rivaroxaban-induced MGIB. These risk factors were used to establish the nomogram. The area under the curve of the nomogram was 0.833 (95%CI, 0.782-0.866), the Brier score was 0.171, the internal validation accuracy was 0.73, and the kappa value was 0.46. The nomogram demonstrated good discrimination, calibration, and clinical applicability. Therefore, it could accurately predict the risk of MGIB in patients treated with rivaroxaban.

24 January 2025 in International Journal of Surgery
Verified
Journal Article
Open access
YDYongqi Dong
Yongqi Dong
HXHongyan Xu
Hongyan Xu
WYWanli Yu
Wanli Yu
ZLZijing Liu
Zijing Liu
GZGang Zhao
Gang Zhao
ZLZebin Lin
Zebin Lin
Introduction: What interventions effectively prevent postoperative stenosis following endoscopic resection (ER) of superficial esophageal cancer? This study aimed to identify effective interventions or combinations through a systematic review and network meta-analysis. Methods: Six databases were systematically searched for eligible studies up to 30 April 2023, on interventions to prevent esophageal stenosis post-ER. Odds ratios (ORs) evaluated stenosis rate (primary outcome) and complications (secondary outcome), while mean differences (MD) evaluated endoscopic balloon dilatation (EBD) sessions post-stenosis. Results: Twenty-three studies involving 1271 patients and 11 different interventions were included. Eight interventions were effective in preventing post-ER stenosis: oral hydrocortisone sodium succinate and aluminum phosphate gel (OHA) (OR: 0.02, 95% credible interval [CrI]: 0.00–0.11), polyglycolic acid (PGA) + ST (OR: 0.02, 95% CrI: 0.00–0.23), oral tranilast (OT) + preemptive endoscopic balloon dilatation (PEBD) (OR: 0.08, 95% CrI: 0.01–0.77), botulinum toxin (BT) (OR: 0.10, 95% CrI: 0.03–0.32), ST (OR: 0.08, 95% CrI: 0.01–0.67), oral steroid (OS) (OR: 0.11, 95% CrI: 0.05–0.28), endoscopic triamcinolone injection (ETI) + OS (OR: 0.17, 95% CrI: 0.07–0.42), and ETI (OR: 0.18, 95% CrI: 0.11–0.30). Five interventions significantly reduced EBD sessions: PGA + ST (MD: −5.78, 95% CrI: −11.04 to −1.21), ETI + OS (MD: −3.27, 95% CrI: −5.37 to −0.72), OS (MD: −6.18, 95% CrI: −9.43 to −3.38), ETI (MD: −3.81, 95% CrI: −5.74 to −1.99), and BT (MD: −2.16, 95% CrI: −4.12 to −0.40). None of the interventions significantly increased complications. Conclusions: This study confirmed the efficacy of OS, ETI, and ETI + OS and verified five other interventions (OHA, PGA + ST, OT + PEBD, BT, and ST) in preventing stenosis. Notably, PGA + ST and BT also reduced the number of EBD sessions.